Ancora Advisors’s NovoCure NVCR Stock Holding History

Ancora Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.16K	Sell	749 -292	-28%	-$3.65K	﹤0.01%	1829
2025 Q4	$13.5K	Buy	+1,041	New	+$13.4K	﹤0.01%	1698
2022 Q4	–	Sell	-6	Closed	–	–	1899
2022 Q3	$0	Hold	6	–	–	﹤0.01%	2129
2022 Q2	$0	Buy	+6	New	+$452	﹤0.01%	2304
2021 Q2	–	Sell	-50	Closed	-$7K	–	1983
2021 Q1	$7K	Buy	+50	New	+$7.91K	﹤0.01%	1511
2020 Q2	–	Sell	-150	Closed	-$10K	–	1402
2020 Q1	$10K	Buy	+150	New	+$11.9K	﹤0.01%	1189

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Ancora Advisors's NVCR Position: Q1 2026 in Review

Ancora Advisors reduced its NovoCure (NVCR) stake by 28% in Q1 2026, selling an estimated $3.65K and leaving 749 shares worth $8.16K. The position accounts for ﹤0.01% of the portfolio, ranked #1829.

Ancora Advisors first reported a position in NVCR in Q1 2020 and has held it in 6 quarters since. The position peaked at $13.5K in Q4 2025. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

Ancora Advisors held 749 shares of NovoCure worth $8.16K as of Q1 2026.
Ancora Advisors sold 292 NovoCure shares in Q1 2026, an estimated $3.65K.
NovoCure made up ﹤0.01% of Ancora Advisors's portfolio in Q1 2026, its #1829 holding.
Ancora Advisors first reported a position in NovoCure in Q1 2020 and has held it in 6 quarters since.
Ancora Advisors's NovoCure position peaked at $13.5K in Q4 2025.
222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Ancora Advisors's 13F filing for Q1 2026, filed 15 May 2026.